MyeloMATCH MM1YA-CTG01 (Acute Myeloid Leukemia) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if 2 different experimental drug combinations can improve outcomes for people who are newly diagnosed with AML. We want to compare the outcomes from the standard treatment (cytarabine + daunorubicin) to the following experimental regimens:
- Venetoclax + cytarabine + daunorubicin
- Venetoclax + azacitidine
What is the Condition Being Studied?
Acute Myeloid Leukemia (AML)
Who Can Participate in the Study?
Adults ages 18-59 who:
- Are newly diagnosed with AML
- Have not received any previous treatment for AML
- Are registered to the Master Screening and Re-Assessment Protocol (myeloMATCH MSRP)
For more information, contact the study team at nick.jeffries@duke.edu.
Age Group
Adults
What is Involved?
If you choose to join this study, you will get a random assignment (random chance) to 1 of 3 groups:
- Group 1: venetoclax + cytarabine + daunorubicin (experimental regimen); OR
- Group 2: venetoclax + azacitidine (experimental regimen); OR
- Group 3: cytarabine + daunorubicin (standard treatment)
Study Details
Full Title
Myelomatch MM1YA-CTG01: A MEASURABLE RESIDUAL DISEASE (MRD) FOCUSED, PHASE II STUDY OF VENETOCLAX PLUS CHEMOTHERAPY FOR NEWLY DIAGNOSED YOUNGER PATIENTS WITH INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA: A TIER 1 MYELOMATCH CLINICAL TRIAL
Principal Investigator
Hematologic Oncologist
Protocol Number
IRB:
PRO00116800
NCT:
NCT05554393
Phase
Phase
II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment